

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

08 Jul 2026

### The effect of vitamin D and E vaginal suppository on vaginal atrophy in women with breast cancer who taking tamoxifen

#### Protocol summary

##### Summary

The aim of this study is to compare the effectiveness of vitamin D and E vaginal suppository on vaginal atrophy in women with breast cancer who taking tamoxifen. Material and Method: this randomized, double blind controlled trial will carry out at in Motahari breast clinic, Shiraz. A total of 150 women with breast cancer with symptoms of vaginal atrophy are randomly assigned to three groups to receive vaginal suppositories. 50 patients will take placebo vaginal suppositories containing 2 gr base material, (Suppocire AS2), 50 patients will take vitamin D vaginal suppositories (1000 IU Vitamin D equivalent to 0/025 mg of vitamin D in addition to the base material), and 50 patients will take vitamin E vaginal suppositories (1 mg vitamin E in addition to the base material). Symptoms of vaginal atrophy are confirmed by assessing vaginal PH (by PH indicator strip, construction by Sigma-Aldrich Germany with accuracy of 0.5), measuring vaginal maturation index (VMI), and subjective symptoms of vaginal atrophy according to self-assessment urogenital atrophy questionnaire (UAQ). If vaginal atrophy is approved (PH Score of 5 or greater than 5, VMI score 52 or less and at least one of the items of the UAQ), 14 vaginal suppositories will be given to any person. After two weeks, the other 14 vaginal suppositories will be given and subjective symptoms of vaginal atrophy will be assessed by UAQ and the vaginal PH is measured. After two weeks, besides the delivery of the remaining 28 suppositories, subjective symptoms of vaginal atrophy is evaluated and vaginal PH is measured. Four weeks later, in addition to evaluating subjective symptoms of vaginal atrophy, vaginal PH level and the vaginal maturation index is also checked.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2016100229683N2**

Registration date: **2016-10-31, 1395/08/10**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2016-10-31, 1395/08/10

##### Registrant information

###### Name

zahra keshavarzi

###### Name of organization / entity

School of Nursing and Midwifery, Shiraz University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 71 4345 5122

###### Email address

stud2420170253@sums.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Vice chancellor for research, Shiraz University of Medical Sciences

##### Expected recruitment start date

2016-10-05, 1395/07/14

##### Expected recruitment end date

2017-02-02, 1395/11/14

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of vitamin D and E vaginal suppository on

vaginal atrophy in women with breast cancer who taking tamoxifen

## Public title

Non Hormonal Treatment of Vaginal Atrophy

## Purpose

Treatment

## Inclusion/Exclusion criteria

Inclusion criteria: being married; having stage 1 and 2 breast cancer based on surgery staging; use of tamoxifen; non-use of chemotherapy or radiation during this study; aged under 50 years; with at least one of the symptoms of the self-assessment urogenital atrophy questionnaire; normal Pap smear within the last 3 years; no proven cancer in other organs of the body based on the results recorded in patient records; having sexual activity. Exclusion criteria: vaginal infection (confirmed by Microbiological analysis); abnormal Pap smear; estrogen therapy during the past 8 weeks; unexplained vaginal bleeding; recurrent disease based on the diagnostic results recorded in patient records; smoking cigarette.

## Age

From **17 years** old to **50 years** old

## Gender

Female

## Phase

2

## Groups that have been masked

*No information*

## Sample size

Target sample size: **150**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Double blinded

## Blinding description

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Shiraz University of Medical Sciences

##### Street address

Department of Research and Information Technology, Shiraz University of Medical Sciences, , Zand Blvd., Shiraz, Iran

##### City

Shiraz

##### Postal code

72823235 009871

## Approval date

2016-06-26, 1395/04/06

## Ethics committee reference number

IR.SUMS.REC.1395.63

## Health conditions studied

### 1

#### Description of health condition studied

: Vaginal Atrophy

#### ICD-10 code

N95. 3

#### ICD-10 code description

Diseases of the genitourinary system (N00-N99)

## Primary outcomes

### 1

#### Description

Vaginal ph

#### Timepoint

Before intervention, Two weeks after the intervention, Four weeks after intervention, eight weeks after intervention

#### Method of measurement

PH indicator strip

## Secondary outcomes

### 1

#### Description

Vaginal cell Maturation

#### Timepoint

Before intervention, eight weeks after intervention

#### Method of measurement

Vaginal Maturation Index

### 2

#### Description

Symptoms of vaginal atrophy

#### Timepoint

Before intervention, Two weeks after the intervention, Four weeks after intervention, eight weeks after intervention

#### Method of measurement

Self-assessment urogenital atrophy questionnaire (UAQ)

## Intervention groups

### 1

#### Description

Group 1, will be received an intervention that included vaginal suppositories vitamin D (1000 IU Vitamin D in addition to 2 gr the base material), once a day for 2 months

**Category**

Treatment - Drugs

**2****Description**

Group 2, will be received an intervention that included vaginal suppositories vitamin E, (1 mg vitamin E in addition to 2 gr the base material), once a day for 2 months

**Category**

Treatment - Drugs

**3****Description**

Control group, the women in control group will be received placebo vaginal suppositories containing 2 gr base material, (Suppocire AS2), once a day for 2 months

**Category**

N/A

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Motahari Breast Clinic, Shiraz

**Full name of responsible person**

Zahra keshavarzi

**Street address**

Midwifery Department, School of Nursing and Midwifery, Nemazee Square, Zand Blvd. Shiraz, Iran.

**City**

Shiraz

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Vice chancellor for research, Shiraz University of Medical Sciences

**Full name of responsible person**

Dr. Seyed Basir Hashemi

**Street address**

Vice-Chancellor for Research, Shiraz University of Medical Sciences, Zand Blvd., Shiraz, Iran

**City**

Shiraz

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research, Shiraz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

**Person responsible for general inquiries****Contact****Name of organization / entity**

School of Nursing and Midwifery, Shiraz University of Medical Sciences

**Full name of responsible person**

Dr Roksana Janghorban

**Position**

Assistant Professor/ PhD

**Other areas of specialty/work****Street address**

Midwifery Department, School of Nursing and Midwifery, Nemazee Square, Zand Blvd. Shiraz, Iran.

**City**

Shiraz

**Postal code****Phone**

+98 71 3647 4254

**Fax****Email**

janghorban@sums.ac.ir

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

School of Nursing and Midwifery, Nemazee Square, Zand Blvd. Shiraz, Iran

**Full name of responsible person**

Dr. Roksana Janghorban

**Position**

Assistant Professor/ PhD

**Other areas of specialty/work****Street address**

Midwifery Department, School of Nursing and Midwifery, Nemazee Square, Zand Blvd. Shiraz, Iran.

**City**

Shiraz

**Postal code****Phone**

+98 71 3647 4254

**Fax****Email**

janghorban@sums.ac.ir

**Web page address****Person responsible for updating data****Contact**

**Name of organization / entity**

School of Nursing and Midwifery, Nemazee Square,  
Zand Blvd. Shiraz, Iran.

**Full name of responsible person**

Dr. Roksana Janghorban

**Position**

Assistant Professor/ PhD

**Other areas of specialty/work****Street address**

Midwifery Department, School of Nursing and  
Midwifery, Nemazee Square, Zand Blvd. Shiraz, Iran.

**City**

Shiraz

**Postal code****Phone**

+98 71 3647 4254

**Fax****Email**

janghorban@sums.ac.ir

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*